Different inhibitory effect of imatinib on phosphorylation of mitogen-activated protein kinase and Akt and on proliferation in cells expressing different types of mutant platelet-derived growth factor receptor-?-Reference-Cited by-同舟云学术

Different inhibitory effect of imatinib on phosphorylation of mitogen-activated protein kinase and Akt and on proliferation in cells expressing different types of mutant platelet-derived growth factor receptor-?

Published:2004 Issue:3 Volume:111 Page:317-321
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Ohashi Akiko,Kinoshita Kazuo,Isozaki Koji,Nishida Toshirou,Shinomura Yasuhisa,Kitamura Yukihiko,Hirota Seiichi

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference26 articles.

1. Gain-of-Function Mutations of c- kit in Human Gastrointestinal Stromal Tumors

2. Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand.

3. KIT Extracellular and Kinase Domain Mutations in Gastrointestinal Stromal Tumors

4. Gain-of-function mutation at the extracellular domain of KIT in gastrointestinal stromal tumours

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Imatinib mesylate use in refractory eosinophilic granulomatosis with polyangiitis: a literature review and a case report;Clinical Rheumatology;2018-03-21

2. L’imatinib mésylate a-t-il un rôle dans le traitement de la granulomatose éosinophilique avec polyangéite ?;Revue du Rhumatisme;2015-03

3. Is there a role for imatinib mesylate in the treatment of eosinophilic granulomatosis with polyangiitis?;Joint Bone Spine;2015-01

4. Extracellular domain c-kit mutation with duplication of Ser501Ala502 found in gastrointestinal stromal tumors is more imatinib- and nilotinib-sensitive than that with duplication of Ala502Tyr503;LAB INVEST;2013

5. Efficacy and safety profile of imatinib mesylate (ST1571) in Japanese patients with advanced gastrointestinal stromal tumors: a phase II study (STI571B1202);International Journal of Clinical Oncology;2008-06